DavidMJackmanMD

Hematologic Oncology, Thoracic Cancer

Medical Director of Clinical Pathways, Dana-Farber Cancer Institute; Senior Physician, DFCI; Assistant Professor of Medicine, Harvard Medical School

Join to view full profile

Dr. Jackman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Jackman's full profile

Already have an account?

Office
Dana-Farber Cancer Institute
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-3468

Fax+1 617-632-5786
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2006
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2000 - 2003
The Warren Alpert Medical School of Brown UniversityClass of 2000

Certifications & Licensure

ME State Medical License Current
FL State Medical License 2023 - Present
NH State Medical License 2009 - 2026
MA State Medical License 2004 - 2025
OH State Medical License 2023 - 2025
CT State Medical License 2023 - 2025
VT State Medical License 2023 - 2024
RI State Medical License 2023 - 2024
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC Start of enrollment: 2010 Feb 01
Completed
Phase 2
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants Start of enrollment: 2013 Dec 12
Terminated
Phase 2
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma Start of enrollment: 2016 Jul 01
Completed
Phase 2
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) Start of enrollment: 2015 Aug 12
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Early Findings on the Use of Clinical Pathways for Management of Unwarranted Variation in Cancer Care.
David M. Jackman, Emily Foster, Joanna M. Hamilton, Carole Kathleen Tremonti, Craig A. Bunnell, Sherri O. Stuver, Joseph O. Jacobson> ;American Journal of Medical Quality. 2021 Jun 8
Lessons from the front: designing and implementing clinical pathways by and for clinicians.
David M. Jackman, Joanna M. Hamilton, Emily Foster, Craig A. Bunnell, Louis Culot, Carole Kathleen Tremonti, Joseph O. Jacobson> ;The American Journal of Managed Care. 2020 Feb 1
28 citations
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
Lecia V. Sequist, Jhanelle E. Gray, Wael A. Harb, Ariel Lopez-Chavez, Robert C. Doebele, Manuel Modiano, David M. Jackman, Maria Q. Baggstrom, Akin Atmaca, Enriqueta F...> ;The Oncologist. 2019 Aug 1
14 citations
Implementation to Optimization: A Tailored, Data-Driven Approach to Improve Provider Efficiency and Confidence in Use of the Electronic Medical Record.
Sarah Kadish, Erica L. Mayer, David M. Jackman, Mark Pomerantz, Lauren Brady, Audra Dimitriadis, Jessica Cleveland, Andrew J. Wagner> ;Journal of Oncology Practice. 2018 Jun 25
351 citations
Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.
Douglas E. Wood, Ella A. Kazerooni, Scott Baum, Georgie A. Eapen, David S. Ettinger, Lifang Hou, David M. Jackman, Donald Klippenstein, Rohit Kumar, Rudy P. Lackner, L...> ;Journal of the National Comprehensive Cancer Network. 2018 Apr 1
471 citations
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
Scott N. Gettinger, Leora Horn, David M. Jackman, David R. Spigel, Scott J. Antonia, Matthew D. Hellmann, John D. Powderly, Rebecca S. Heist, Lecia V. Sequist, David S...> ;Journal of Clinical Oncology. 2018 Mar 23
37 citations
Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer.
David M. Jackman, Yichen Zhang, Carole Kathleen Dalby, Tom C. Nguyen, Julia M. Nagle, Christine A. Lydon, Michael S. Rabin, Kristen K. McNiff, Belen Fraile, Joseph O. ...> ;Journal of Oncology Practice. 2017 Mar 4
89 citations
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Masahiko Yanagita, Amanda J. Redig, Cloud P. Paweletz, Suzanne E. Dahlberg, Allison O'Connell, Nora Feeney, Myriam Taibi, David Boucher, Geoffrey R. Oxnard, Bruce E. J...> ;Clinical Cancer Research. 2016 Dec 15
15 citations
Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC
Vishesh Agrawal, Thibaud P. Coroller, Ying Hou, Stephanie W. Lee, John Romano, Elizabeth H. Baldini, Aileen B. Chen, David M. Jackman, David Kozono, Scott J. Swanson, ...> ;Lung Cancer. 2016 Dec 1
13 citations
Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotini...
Amanda J. Redig, Daniel B. Costa, Myriam Taibi, David Boucher, Bruce E. Johnson, Pasi A. Jänne, David M. Jackman> ;JAMA Oncology. 2016 Sep 1
12 citations
Advanced nodal stage predicts venous thromboembolism in patients with locally advanced non-small cell lung cancer
Richard Li, Gretchen Hermann, Elizabeth H. Baldini, Aileen B. Chen, David M. Jackman, David Kozono, Paul Nguyen, Anju Nohria, Graham Powell, Raymond H. Mak> ;Lung Cancer. 2016 Jun 1
444 citations
MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Mark M. Awad, Geoffrey R. Oxnard, David M. Jackman, Daniel O. Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C. Heng, Suzanne E. Dahlberg, Pasi A. Jänne, Suman ...> ;Journal of Clinical Oncology. 2016 Jan 4
223 citations
Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
Jessica J. Lin, Stephanie Cardarella, Christine A. Lydon, Suzanne E. Dahlberg, David M. Jackman, Pasi A. Jänne, Bruce E. Johnson> ;Journal of Thoracic Oncology. 2016 Apr 1
185 citations
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
Antonio Calles, Xiaoyun Liao, Lynette M. Sholl, Scott J. Rodig, Gordon J. Freeman, Mohit Butaney, Christine A. Lydon, Suzanne E. Dahlberg, F. Stephen Hodi, Geoffrey R....> ;Journal of Thoracic Oncology. 2015 Dec 1
163 citations
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
Anna F. Farago, Long P. Le, Zongli Zheng, Alona Muzikansky, Alexander Drilon, Manish R. Patel, Todd M. Bauer, Stephen V. Liu, Sai-Hong Ignatius Ou, David M. Jackman, D...> ;Journal of Thoracic Oncology. 2015 Dec 1
35 citations
Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.
Peter C. Lo, Suzanne E. Dahlberg, Mizuki Nishino, Bruce E. Johnson, Lecia V. Sequist, David M. Jackman, Pasi A. Jänne, Geoffrey R. Oxnard> ;Cancer. 2015 Aug 1
51 citations
Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival.
Mizuki Nishino, Stephanie Cardarella, Suzanne E. Dahlberg, Tetsuro Araki, Christine A. Lydon, David M. Jackman, Michael S. Rabin, Hiroto Hatabu, Bruce E. Johnson> ;European Journal of Radiology. 2015 May 1
961 citations
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell...
Scott N. Gettinger, Leora Horn, Leena Gandhi, David R. Spigel, Scott J. Antonia, Naiyer A. Rizvi, John D. Powderly, Rebecca S. Heist, Richard D. Carvajal, David M. Jac...> ;Journal of Clinical Oncology. 2015 Apr 20
87 citations
Immunohistochemical loss of LKB1 is a biomarker for more aggressive biology in KRAS mutant lung adenocarcinoma.
Antonio Calles, Lynette M. Sholl, Scott J. Rodig, Ashley Pelton, Jason L. Hornick, Mohit Butaney, Christine A. Lydon, Suzanne E. Dahlberg, Geoffrey R. Oxnard, David M....> ;Clinical Cancer Research. 2015 Mar 3
74 citations
A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer.
David M. Jackman, Leigh Anne Cioffredi, Lorraine Jacobs, Farhana Sharmeen, Linda K. Morse, Joan Lucca, Scott R. Plotkin, Paul Marcoux, Michael S. Rabin, Thomas J. Lync...> ;Oncotarget. 2015 Mar 2
94 citations
Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines.
Douglas E. Wood, Ella A. Kazerooni, Scott Baum, Mark T. Dransfield, Georgie A. Eapen, David S. Ettinger, Lifang Hou, David M. Jackman, Donald Klippenstein, Rohit Kumar...> ;Journal of the National Comprehensive Cancer Network. 2015 Jan 1
67 citations
Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival.
Phillip J. Gray, Raymond H. Mak, Beow Y. Yeap, Sarah K Cryer, Nancy E. Pinnell, Laura W. Christianson, David J. Sher, Nils D. Arvold, Elizabeth H. Baldini, Aileen B. C...> ;Lung Cancer. 2014 Aug 1
23 citations
Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to th...
Mizuki Nishino, David M. Jackman, Pamela J. DiPiro, Hiroto Hatabu, Pasi A. Jänne, Bruce E. Johnson> ;Clinical Radiology. 2014 Aug 1
119 citations
Definitive Primary Therapy in Patients Presenting With Oligometastatic Non-Small Cell Lung Cancer
Ravi B. Parikh, Angel M. Cronin, David Kozono, Geoffrey R. Oxnard, Raymond H. Mak, David M. Jackman, Peter C. Lo, Elizabeth H. Baldini, Bruce E. Johnson, Aileen B. Chen> ;International Journal of Radiation Oncology, Biology, Physics. 2014 Jul 15
608 citations
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA
Geoffrey R. Oxnard, Cloud P. Paweletz, Yanan Kuang, Stacy L. Mach, Allison O'Connell, Melissa M. Messineo, Jason J. Luke, Mohit Butaney, Paul Kirschmeier, David M. Jac...> ;Clinical Cancer Research. 2014 Mar 15
Join now to see all

Press Mentions

Cancer Without Chemotherapy: ‘A Totally Different World’September 27th, 2021
What Mesothelioma Awareness Day Means to a SurvivorSeptember 26th, 2019
Royal Philips : Philips IntelliSpace Precision Medicine Oncology Pathways Powered by Dana-Farber Is Now LiveSeptember 11th, 2019
Join now to see all